PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-I
NCT ID: NCT04903665
Last Updated: 2022-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
495 participants
OBSERVATIONAL
2021-02-11
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-II
NCT06001099
Assessment of Prognosis Using Peripheral Blood Circulating Tumor DNA in Patients With Cervical Cancer
NCT05602831
The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer
NCT06283875
Studying Biomarkers in Blood Samples From Patients With Invasive Cervical Cancer
NCT01074424
The Application of Invivo Microscopy Imaging in the Early Diagnosis of Cervical Cancer
NCT02955667
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cancer Arm
Participants with new diagnosis of gynecologic cancers, from whom blood samples will be collected.
Multi-cancer early detection test
Blood collection and multi-cancer early detection testing
Benign Arm
Participants with new diagnosis of benign gynecologic diseases, from whom blood samples will be collected.
Multi-cancer early detection test
Blood collection and multi-cancer early detection testing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Multi-cancer early detection test
Blood collection and multi-cancer early detection testing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to provide a written informed consent
* Confirmed diagnosis or highly suspicious cases of gynecologic malignancies
* No prior or ongoing anti-cancer therapy (local or systematic) prior to study blood draw
* Age 18 years or older
* Able to provide a written informed consent
* Confirmed diagnosis of benign gynecologic diseases
* No prior radical treatment of the benign diseases prior to study blood draw
Exclusion Criteria
* Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant
* Recipients of blood transfusion within 7 days prior to study blood draw
* Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer
* Pregnancy or lactating women
* Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant
* Recipients of blood transfusion within 7 days prior to study blood draw
* Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangzhou Burning Rock Bioengineering Ltd.
INDUSTRY
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiaohua Wu MD
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaohua Wu, M.D.&Ph.D
Role: PRINCIPAL_INVESTIGATOR
Department of Gynecological Oncology, Fudan University Shanghai Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FDZL-2021002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.